BioSpace News Archive

Galderma announces that the U.S. Food and Drug Administration (FDA) has approved Restylane ® Kysse for lip augmentation and the correction of upper perioral rhytids (wrinkles around upper lips) in adults over the age of 21.

Ichnos Sciences Inc. is pleased to announce the appointment of David Lubner as an independent member of its Board of Directors. David has more than 20 years of finance and executive leadership experience and currently serves as Executive Vice President and Chief Financial Officer (CFO) of Ra Pharma, acquired by UCB in April 2020 .

Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S. Food & Drug Administration (“FDA”) has accepted the Company’s Investigational New Drug application (“IND”) to initiate a Phase 2 proof-of-concept study to evaluate the therapeutic poten

Insmed Incorporated announced that it priced a registered underwritten public offering of 9,700,000 shares of its common stock at a price to the public of $23.25 per share.

Portage Biotech Inc. (“Portage” or the “Company”) wishes to provide an update on a subsidiary company, Saugatuck Therapeutics Ltd. (“Saugatuck”). Portage Biotech Inc. holds an 70% equity interest in Saugatuck. Portage is pleased to announce that initial proof of concept of the n

Immunomic Therapeutics, Inc., (“ITI”) a privately-held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced today the appointment of five new members to its Board of Directors from HLB, Co. Ltd (“HLB”) and its HLB Bio subsidiaries. “I am delighted to welcome

Licensed technologies include use of Genprex’s TUSC2 gene therapy combined with immunotherapy drugs

Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology, neuroscience and biodefense, announced that they have successfully closed their most recent funding round totaling $5 million.

LifeMax Laboratories, Inc., a private company focused on developing first-in-class or best-in-class therapeutics for the treatment of orphan diseases with few or no therapeutic options, announced the appointment of Michael Huang, MD, as its Chief Medical Officer.

Century Therapeutics, developer of induced pluripotent stem cell -derived allogeneic cell therapies for cancer, announced the formation of its Scientific Advisory Board to include several renowned experts in the fields of developmental and stem cell biology, genetics, and immuno-oncology.